The study, also known as RV 144, began in 2003 and enrolled more than 16,000 HIV-negative Thai men and women between the ages of 18 and 30. The first announcement of data from this test-of concept trial is expected in late September.
The study was conducted by the Thai Ministry of Public Health, sponsored by the US Army Surgeon General, and managed by the US Military HIV Research Program.
The US National Institute of Allergy and Infectious Diseases (NIAID) and the US Army Medical Research and Materiel Command provided funding, with in-kind contributions from vaccine manufacturers Sanofi Pasteur and Global Solutions for Infectious Diseases (GSID). (GSID now holds the intellectual property rights to the AIDSVAX vaccine included in the trial that was originally developed and previously owned by VaxGen.)
The study was conducted by the Thai Ministry of Public Health, sponsored by the US Army Surgeon General, and managed by the US Military HIV Research Program. The US National Institute of Allergy and Infectious Diseases (NIAID) and the US Army Medical Research and Materiel Command provided funding, with in-kind contributions from vaccine manufacturers Sanofi Pasteur and Global Solutions for Infectious Diseases (GSID). (GSID now holds the intellectual property rights to the AIDSVAX vaccine included in the trial that was originally developed and previously owned by VaxGen.)
· Access the document above – designed by the AIDS Vaccine Advocacy Coalition to help advocates prepare for the initial announcement. AVAC will provide an updated and expanded version of this report, which will discuss the results following their release in October.
